
Robo.ai subsidiary Robus enters Pakistani market with first commercial vehicle deliveries
Robo.ai (NASDAQ:AIIO), an emerging leader in intelligent transportation solutions, announced on April 10, 2026, that its subsidiary, Robus, has officially commenced deliveries of its initial commercial prototype vehicles in Pakistan.
The move marks a critical operational shift for the company as it moves from the prototyping phase toward scaled revenue generation in high-growth emerging markets.
The first batch of vehicles was delivered to local partners as part of a strategic rollout aimed at the Pakistani logistics and industrial sectors.
The milestone follows the successful completion of the manufacturing phase for the initial prototype fleet, which was designed to test the viability of the Robus modular platform under regional environmental and infrastructure conditions.
Robus has identified Pakistan as a priority hub for the adoption of "new-energy" commercial vehicles.
The company’s modular platform is engineered to be adaptable across various use cases—including public transportation and industrial freight—with a primary focus on reducing the total cost of ownership (TCO) for fleet operators through energy efficiency and smart diagnostic tools.
The Pakistani market has recently seen increased interest in green energy initiatives as the government seeks to modernize its transport grid and reduce reliance on imported fossil fuels.
Robo.ai’s entry into the market aligns with these broader economic shifts, offering a platform that integrates autonomous-ready hardware with high-capacity battery technology.
Looking ahead, Robo.ai plans to ramp up manufacturing capacity throughout the remainder of 2026 to support a steady cadence of deliveries.
More from United States
Anthropic prices IPO above range at $83, sources say
Palo Alto Networks revenue advances to $3.44 billion, up 39%
Woodward records 22% sales growth in fiscal 2026 as revenue hits $4.4B
C3is reports $1.2 million Q3 net loss as revenue rises
Cosmos Health revenue hits $53.6 million, up 17.6%
Summit launches Phase III lung cancer trial for ivonescimab